Drug approved for inherited blood disorder

(HealthDay)—Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.

Thalassemia typically leads to the production of fewer and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.

The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.

The drug is produced by Novartis, East Hanover, N.J.

More information: The U.S. National Heart Lung and Blood Institute has more about thalassemia.

More Information

add to favorites email to friend print save as pdf

Related Stories

Blood protein offers help against anemia

Jan 26, 2010

A new study shows that a protein found in blood alleviates anemia, a condition in which the body's tissues don't get enough oxygen from the blood. In this animal study, injections of the protein, known as transferrin, also ...

MIT uncovers key blood protein

Oct 11, 2007

Scientists working in the only lab at MIT doing hematology research have uncovered a protein that plays a key role in the recycling of iron from blood.

Recommended for you

Supercomputers link proteins to drug side effects

1 hour ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

9 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments